Transaction DateRecipientSharesTypePriceValue
28th October 2020Susan L Bostrom404Grant/award etc.$0.00
21st October 2020Judy Bruner2,009Payment by withholding$51.69$103,845.21
21st October 2020Judy Bruner5,579Exercise of derivative$0.00
14th October 2020Kolleen T Kennedy400Open or private sale$172.01$68,805.08
14th October 2020Kolleen T Kennedy400Exercise of derivative$131.77$52,708.00
8th October 2020Kolleen T Kennedy543Open or private sale$171.91$93,346.97
8th October 2020Kolleen T Kennedy543Exercise of derivative$112.82$61,261.26
21st September 2020Dow R Wilson38,907Open or private sale$172.43$6,708,730.12
21st September 2020Dow R Wilson38,907Exercise of derivative$67.12$2,611,437.84
14th September 2020Kolleen T Kennedy400Exercise of derivative$131.77$52,708.00
Varian Medical Systems
Varian Medical Systems logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

Varian Medical Systems, Inc. engages in the manufacture of medical devices and software for treating cancer and other medical conditions. It operates through the Oncology Systems and Proton Solutions segments. The Proton solutions segment delivers proton therapy, a form of external beam radiotherapy.

Ticker: VAR
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 203527
Employees: 10062
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $769 M (0%)
Inventory, Net: $600 M (0%)
Assets, Current: $3 B (9%)
Other Assets, Noncurrent: $387 M (-2%)
Assets: $4 B (8%)
Short-term Debt: $580 M (41%)
Accounts Payable, Current: $164 M (-33%)
Accrued Liabilities, Current: $468 M (1%)
Liabilities, Current: $2 B (5%)
Other Liabilities, Noncurrent: $417 M (0%)
Liabilities: $3 B (8%)
Common Stock, Value, Issued: $91 M (0%)
Common Stock, Shares, Issued: $91 (0%)
Retained Earnings (Accumulated Deficit): $1 B (12%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $114 M (11%)
Stockholders' Equity (Parent): $2 B (9%)
Liabilities and Equity: $4 B (8%)
Revenue: $694 M (0%)
Cost of Revenue: $396 M (-69%)
Gross Margin: $298 M (-70%)
Research and Development: $65 M (-67%)
Restructuring Charges: $14 M (0%)
Operating Income/Loss: $60 M (0%)
Other Income, net: $25 M (-12%)
Provision for income taxes: $24 M (-58%)
EPS (basic): $0.67 (0%)
EPS (diluted): $0.67 (0%)